Status:
WITHDRAWN
Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
International AIDS Vaccine Initiative
Conditions:
HIV Infections
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of and immune response to an HIV DNA vaccine followed by an adenoviral vector HIV vaccine in healthy African adults at risk for HIV...
Detailed Description
Due to the availability of antiretroviral therapy, AIDS-related deaths have lessened in the United States. However, these therapies are widely inaccessible to the developing world. The need for a safe...
Eligibility Criteria
Inclusion
- At risk for HIV
- Have had sexual intercourse with an HIV infected partner OR have had sexual intercourse with more than one person within the 3 months prior to study entry OR infected with a sexually transmitted disease within the 3 months prior to study entry
- Willing to comply with the protocol
- Willing to undergo HIV testing and HIV counseling and receive HIV test results
- Willing to use acceptable forms of contraception
Exclusion
- HIV-1 or HIV-2 infected
- History of immunodeficiency or autoimmune disease
- Use of corticosteroids or immunosuppressive, antiviral, anticancer, or other medications considered significant by investigator within 6 months prior to study entry
- Certain abnormal laboratory values
- Acute or chronic medical condition considered progressive
- Hepatitis B or hepatitis C virus infection or untreated syphilis
- Live attenuated vaccine within 30 days prior to study
- Planned receipt of investigational product within 30 days after first vaccination
- Other medically indicated subunit or killed vaccine within 14 days prior to study entry
- Planned receipt of other medically killed vaccine investigational product within 14 days after first vaccination
- Blood transfusion within 120 days of study entry
- Immunoglobulin within 60 days of study entry
- Participation within the last 3 months, or planned participation in another clinical study of investigational product currently or during the course of this study
- Another investigational HIV vaccine at any time
- History of severe local or systemic reactogenicity to vaccines
- History of severe allergic reactions
- History of recurrent urticaria
- Major psychiatric illness, including any history of schizophrenia or severe psychosis, bipolar disorder requiring therapy, or suicide attempt or ideation in the 3 years prior to study entry
- Uncontrolled hypertension
- Pregnant, breastfeeding, or planning to become pregnant within 4 months following last study vaccination
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00415649
Last Update
November 1 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.